Pike Erika, Stoops William W, Hays Lon R, Glaser Paul E A, Rush Craig R
From the Departments of *Behavioral Science, College of Medicine, †Psychology, College of Arts and Sciences, ‡Psychiatry, and §Anatomy and Neurobiology, College of Medicine, University of Kentucky, Lexington, KY.
J Clin Psychopharmacol. 2014 Dec;34(6):675-81. doi: 10.1097/JCP.0000000000000207.
Agonist replacement may be a viable treatment approach for managing stimulant use disorders. This study sought to determine the effects of D-amphetamine maintenance on methamphetamine self-administration in stimulant using human participants. We predicted that D-amphetamine maintenance would reduce methamphetamine self-administration. Eight participants completed the protocol, which tested 2 D-amphetamine maintenance conditions in counterbalanced order (0 and 40 mg/d). Participants completed 4 experimental sessions under each maintenance condition in which they first sampled 1 of 4 doses of intranasal methamphetamine (0, 10, 20, or 30 mg). Participants then had the opportunity to respond on a computerized progressive-ratio task to earn portions of the sampled methamphetamine dose. Subject-rated drug effect and physiological measures were completed at regular intervals prior to and after sampling methamphetamine. Methamphetamine was self-administered as an orderly function of dose regardless of the maintenance condition. Methamphetamine produced prototypical subject-rated effects on 12 items of the drug-effects questionnaires, 8 of which were attenuated by D-amphetamine maintenance (eg, increased ratings were attenuated on items such as Any Effect, Like Drug, and Willing to Take Again on the Drug Effect Questionnaire). Methamphetamine produced significant increases in systolic blood pressure, which were attenuated by D-amphetamine maintenance compared to placebo maintenance. Methamphetamine was well tolerated during D-amphetamine maintenance and no adverse events occurred. Although D-amphetamine attenuated some subject-rated effects of methamphetamine, the self-administration results are concordant with those of clinical trials showing that D-amphetamine did not reduce methamphetamine use. Unique pharmacological approaches may be needed for treating amphetamine use disorders.
激动剂替代可能是治疗兴奋剂使用障碍的一种可行方法。本研究旨在确定D-苯丙胺维持治疗对使用兴奋剂的人类参与者甲基苯丙胺自我给药的影响。我们预测D-苯丙胺维持治疗会减少甲基苯丙胺的自我给药。八名参与者完成了该方案,该方案以平衡顺序测试了2种D-苯丙胺维持治疗条件(0和40毫克/天)。参与者在每种维持治疗条件下完成4个实验环节,在这些环节中,他们首先对4种鼻内甲基苯丙胺剂量(0、10、20或30毫克)中的1种进行采样。然后,参与者有机会在计算机化的累进比率任务中做出反应,以获取部分采样的甲基苯丙胺剂量。在采样甲基苯丙胺之前和之后定期完成主观评定的药物效果和生理测量。无论维持治疗条件如何,甲基苯丙胺的自我给药都是剂量的有序函数。甲基苯丙胺对药物效果问卷中的12项产生了典型的主观评定效果,其中8项因D-苯丙胺维持治疗而减弱(例如,在药物效果问卷中的“任何效果”、“喜欢药物”和“愿意再次服用”等项目上,增加的评定分数减弱)。甲基苯丙胺使收缩压显著升高,与安慰剂维持治疗相比,D-苯丙胺维持治疗使这种升高减弱。在D-苯丙胺维持治疗期间,甲基苯丙胺耐受性良好,未发生不良事件。尽管D-苯丙胺减弱了甲基苯丙胺的一些主观评定效果,但自我给药结果与临床试验结果一致,表明D-苯丙胺并未减少甲基苯丙胺的使用。治疗苯丙胺使用障碍可能需要独特的药理学方法。